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Abstract  
The prevalence of negative symptoms (NS) at first episode of early-onset psychosis 
(EOP), and their effect on psychosis prognosis is unclear. In a sample of 638 children 
with EOP (aged 10-17 years, 51% male), we assessed (i) the prevalence of NS at first 
presentation to mental health services, and (ii) whether NS predicted eventual 
development of multiple treatment failure (MTF) prior to the age of 18 (defined by 
initiation of a third trial of novel antipsychotic due to prior insufficient response, 
intolerable adverse-effects or non-adherence). Data were extracted from the electronic 
health records held by child inpatient and community-based services in South London, 
UK. Natural language processing tools were used to measure the presence of Marder 
Factor NS and antipsychotic use. The association between presenting with ≥2 NS and 
the development of MTF over a 5-year period was modelled using Cox regression. Out 
of the 638 children, 37.5% showed ≥2 NS at first presentation, and 124 (19.3%) 
developed MTF prior to the age of 18. The presence of NS at first episode was 
significantly associated with MTF (adjusted hazard ratio 1.62, 95% CI 1.07–
2.46; p=.02) after controlling for a number of potential confounders including psychosis 
diagnostic classification, positive symptoms, co-morbid depression, and family history 
of psychosis. Other factors associated with MTF included co-morbid autism spectrum 
disorder, older age at first presentation, Black ethnicity and family history of psychosis. 
In EOP, NS at first episode are prevalent and may help identify a subset of children at 
higher risk of responding poorly to antipsychotics.  
 
Key words: Early-onset psychosis, First-episode psychosis, Negative symptoms, 
Antipsychotic agents, Treatment resistance 
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Introduction  
Early-onset psychosis (EOP), defined as onset before age 18 years, is a severely 
debilitating condition associated with long-term psycho-social impairment.
1
 As a 
diagnostic term, EOP covers a broad range of psychiatric illness including 
schizophrenia spectrum, affective and other non-affective psychotic disorders.
2
 Children 
with EOP often show significant levels of both positive and negative symptoms and 
disorganized behaviour. Relative to adult-onset psychosis, children and adolescents are 
more likely to have a background of longer durations of untreated psychosis, poor pre-
morbid adjustment, and greater number of co-existing conditions, such as 
neurodevelopmental and substance abuse disorders.
3-4
 
 
Compared to work examining the pathogenesis of adult and early-onset
 
psychosis, 
studies which examine prognostic indicators in the years following treatment initiation 
are relative scarce.
1
 From the research conducted, findings suggest that both a longer 
duration of untreated psychosis and poorer premorbid adjustment are associated with 
poorer recovery in EOP. Despite previous evidence from adult-onset samples 
supporting the influence of negative symptoms (NS) on functional outcomes and 
recovery, the effect of NS on the prognosis of EOP remains relatively unexplored. NS 
symptoms include lack of motivation, problems with social interaction or diminished 
emotional range, and involve a loss or deficit in normal functioning.
5-6
 They can be 
enduring and inherent to the core disease process (i.e. primary NS), or caused by other 
factors such as medication side-effects, positive symptoms, concurrent depression or 
limited social stimulation (i.e. secondary NS).
5-6
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At present it is difficult to assess the prognostic implications of NS at a young’s 
person’s first presentation with psychosis.
1
 In adult-onset cases, NS are reportedly 
present at first-episode psychosis in about 30-50% of patients.
7-8
 They are difficult to 
treat and are one of the main contributors to the functional disability observed in 
psychotic illness.
9-15
 In EOP cases, NS are also reportedly stable over time, but little is 
known about the prevalence of these symptoms at first-episode.
16
 Most studies so far 
have focused on early-onset schizophrenia,
17-19
 which may not generalise to the 
heterogeneous population of young people that first present to child and adolescent 
early psychosis intervention services. In addition, prior research findings have been 
limited by small sample sizes, convenience recruitment of more severe cases,  or 
inclusion of those more amenable to taking part in a research study.
1, 4
 
 
The digitisation of mental health records across the world, presents an alternative 
resource for psychosis researchers who wish to study clinical issues “in vivo”.
20
  A 
major strength of these data is their comprehensive inclusion of the whole population of 
interest, and therefore providing highly generalizable results - addressing some of the 
limitations related to selection bias, sample size and attrition commonly found in the 
cohort studies described above. At present, NS research using electronic health records 
(EHR) has been limited. Despite a number of robust rating scales now available to 
assess NS in psychosis,
21-23
 they are inconsistently applied to clinical populations 
treated in routine practice.
24-25
  
 
Computational linguistics or Natural Language Processing (NLP) explores how to make 
computer systems understand and manipulate natural language expressed in text to 
perform desired tasks.
26
 Phenotype algorithms using NLP within clinical text,  are an 
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emerging method of automatically classifying patients with specific diseases, symptoms 
and outcomes.
27
 NLP approaches can discern the meaning or semantic content of text, 
and using pre-specified algorithms, encode text to provide structured output for 
analysis. This provides considerable advantages compared to performing key word 
searches in EHR, especially when accurately targeting certain clinical phenotypes.
27
 For 
example, NLP can discern whether a key word emotional withdrawal in the health 
record refers to a patient or family member, their current or past mental state, or is 
simply a negated item within clinical screening. NLP approaches can use pattern 
recognition via statistical or machine learning methods to identify a phenotype or 
exposure of interest within the EHR. Parameters around accuracy can be stipulated, 
allowing uncertainty on whether an event or phenotype is a true positive, which can be 
accounted in later analysis. Investigators have largely adopted this approach in i2b2 
(Informatics for Integrating Biology and the Bedside), a US consortium, based at 
Harvard/MIT Health Science division and Partners HealthCare System in Boston, 
Massachusetts.
28
  
 
In a large naturalistic sample of children and adolescents first presenting to services 
with EOP, we examined the prevalence of NS recorded in the mental health record at 
initial contact with psychiatric services. To address the limited structured information 
available on NS, we used a machine learning NLP approach, validated in adult samples, 
to extract NS data within the EHR. To explore NS as potential prognostic indicator, we 
examined whether NS at first episode predicted antipsychotic treatment failure,  using a 
pragmatic measure of treatment failure, as defined by initiation of a third trial of novel 
antipsychotic (due to prior insufficient response, intolerable adverse-effects or non-
adherence), which we termed multiple treatment failure (MTF).
29
 Previous work in 
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adult-onset samples, suggests that NS characterize psychotic disorders with non-
hyperdopaminergic pathophysiology,
30-31
 which is supported by clinical evidence that 
NS in the first-episode are associated with poorer response to antidopaminergic effects 
of current antipsychotic treatment.
30, 32
 Therefore, we predicted that EOP patients with 
NS at presentation would be more likely to experience MTF. We also expected that this 
association would remain after taking account of potential confounders, including type 
of psychotic disorder, positive symptoms, family history of psychosis, co-morbid 
depression, and additional markers of premorbid neurodevelopmental difficulties such 
as co-occurring autism spectrum disorders (ASD), hyperkinetic disorder and intellectual 
disability. 
 
Methods 
Study design and study sample 
A complete description of the study design and sample selection is provided 
elsewhere.
29
 In brief, the sample consisted of a clinical cohort of all those individuals 
with a first episode of any psychotic disorder who were referred to child and adolescent 
mental health services (CAMHS) – including inpatient, outpatient and early intervention 
for psychosis services - in South London and Maudsley NHS Foundation Trust (SLaM), 
UK, from January 1
st
 2008 to December 31
st
 2014. Over this time, SLAM delivered all 
aspects of inpatient and community based child mental healthcare to approximately 
250.000 children residing in four London boroughs, and specialist provision to children 
resident outside the boroughs where local area services (such as inpatient facilities) 
were unavailable. Most children experiencing a psychotic disorder within the SLaM 
catchment area of South London were likely to present to SLaM services and included 
in this study: the private sector has very limited involvement in child mental health 
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within the area, and children with psychosis, relative to adults, usually come to the 
attention of services relatively early.
34
 
 
The data were extracted using the Clinical Record Interactive Search (CRIS) 
application: a de-identified record database containing the EHR of over 34.400 child 
and adolescent cases held at the UK National Institute for Health Research (NIHR) 
Biomedical Research Centre (BRC) for Mental Health.
35-36
  Data from structured text 
fields was extracted and missing structured data was supplemented by natural language 
processing tools [Generalised Architecture for Text Engineering (GATE)
37
 and 
TextHunter
38
] which code ‘free text’ from the EHR (i.e. progress notes, mental state 
assessments, discharge summaries, outpatient correspondence). The CRIS resource was 
an approved as anonymised data resource for secondary analysis by Oxfordshire 
Research Ethics Committee C (08/H0606/71+5). This study was approved under NIHR 
BRC CRIS oversight committee (ref: CRIS 14-095). 
 
Inclusion criteria 
Inclusion criteria for participants were: 1) age 10-17 years at the time of first 
presentation to CAMHS (owing to ethics and risk of statistical disclosure, we did not 
include children who were under the age of 10 years); 2) at least one ‘clinically 
relevant’ psychotic disorder diagnosis, based on clinician judgment after comprehensive 
diagnostic interviews and identified from either clinician-recorded structured fields 
(ICD-10 codes F20-F29, F30-31, F32.3, F33.3, F1x.5); or any free text clinician-
recorded ICD-10 diagnosis of ‘schizophrenia’, ‘schizoaffective disorder’, ‘bipolar 
disorder’, ‘depression with psychotic symptoms’, ‘brief psychotic disorder, ‘delusional 
disorder, ‘shared psychotic disorder’, ‘drug-induced psychosis’ and ‘psychosis not 
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otherwise specified (NOS)’, filtered for any clinician-recorded mention of antipsychotic 
treatment after the psychosis diagnosis. The earliest recorded psychosis diagnosis was 
coded as the first-episode diagnosis. For reporting purposes, diagnoses were grouped 
into schizophrenia, schizoaffective disorder, bipolar disorder, psychotic depression, 
drug-induced psychosis, and other psychoses (including brief psychotic disorder, 
delusional disorder, shared psychotic disorder, and psychoses-NOS). A hand-searched 
review of a random sample of 100 records revealed that this identification process had a 
0.98 positive predictive value (PPV) for psychosis. 
 
Figure 1 shows the flowchart for inclusion in the study. Out of the 1033 cases initially 
identified with the GATE tool or through structured diagnoses, only 638 individuals met 
the inclusion criteria for a ‘clinically relevant psychotic disorder’ and age 10-17 years 
and were therefore included, whilst 395 were excluded due to psychosis referring to 
non-primary/differential diagnosis or subthreshold symptoms. 
 
[Fig 1 about here] 
 
 
Extraction of antipsychotic use data and definition of MTF 
As described elsewhere,
29
 we used a previously validated GATE application to identify 
regular antipsychotic prescription trials from the structured medication fields and 
unstructured fields in the EHR.
39-40
 Since no standard criteria for poor antipsychotic 
response or refractory disorder appeared suitable for EOP samples,
41-42
 a proxy was 
created, based on the antipsychotic effectiveness literature,
43-45
 which we termed MTF; 
defined as the initiation of a third trial of a novel antipsychotic due to insufficient 
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response, intolerable adverse effects, non-adherence, or other miscellaneous reasons 
over a 5-year follow-up period from first presentation, or before the age of 18 years, 
whichever came first. Please see Downs et al. 2017 for further details around the 
validation of the MTF outcome and reasons for discontinuation.
29
  
 
Extraction of NS data 
 
A previously validated Natural Language Processing method
8
 was used to find 
statements in the unstructured free-text fields of patients’ EHR which related to the 
presence of NS at baseline (i.e. within 60 days of accepted referral). The method was 
based on a NLP tool called TextHunter [see Jackson et al. (2014) for further details]
38
 
which is a custom-built NLP software tool which interfaces with CRIS. It facilitates 
each of the steps involved in developing a NLP application,
27
 from identifying 
appropriate ontologies and supporting manual annotation, to applying and testing 
sophisticated text based pattern recognition (including support vector machine learning 
approaches) derived from annotated training datasets.  
 
To validate the NLP data extraction, the randomised sample of 100 cases used 
previously was also hand-searched for NS by a master’s level graduate in Early 
Intervention Psychosis studies (HD), blinded to MTF status. The PPV for NS subtypes 
ranged from 0.80 (poverty of speech) to 0.99 (mutism) and sensitivity ranged from 0.62 
(poor motivation) to 0.97 (apathy). For the purposes of this study, Marder negative 
factor items 
21, 46
 from the Positive and Negative Syndrome Scale (PANSS)
23
 were used 
as a framework for characterizing NS (see Table 1 for details). The extracted item 
‘social isolation’ was considered descriptive of both passive apathetic social withdrawal 
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(Marder N4) and active social avoidance (Marder G16). Having mutism, poverty of 
speech or both items recorded on the EHR was counted as a single NS, equivalent to 
lack of spontaneity / flow of conversation (Marder N6). The item psychomotor 
retardation (equivalent to Marder G7) was dropped as an NS due to its low PPV (0.55) 
and sensitivity (0.65). Furthermore, the hand search of the selected 100 cases revealed 
that this item had a low prevalence (~5% of the sample) and always appeared 
acknowledged as an antipsychotic-related adverse effect (hence a secondary NS).  
 
 [Table 1 around here] 
 
A composite ordinal variable, ‘number of NS’ (range 0 – 5) was created by summing 
the total count of the extracted NS. A score of at least two NS was applied a priori to 
determine the presence or absence of NS for analysis. Individuals were categorized as 
having an NS or non-NS profile using the ≥2 Marder Factor NS cut-off. This was 
consistent with previous work that used the two-symptom cut-off to describe deficit 
syndromes in schizophrenia (i.e. primary, enduring NS).
8, 13
 
 
Extraction of other clinical and demographic data 
A number of demographic variables and clinical data within 60 days of study entry (i.e. 
after accepted referral) were also extracted from the health record. Age at referral for 
first-episode psychosis, gender, ethnicity (according to categories defined by the UK 
Office for National Statistics), and index of neighbourhood deprivation for the main 
caregiver residence were extracted.
47
 Data on positive symptom severity around first 
presentation were extracted using TextHunter (see Jackson et al. 2017 for validation 
metrics) which provided the total number of items in the EHR referencing positive 
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symptoms of psychosis including delusions, persecutory and paranoid ideation, and 
hallucinations. Based on the total number of items referenced, individuals were then 
categorised into quartiles. As an additional index of severity we coded inpatient status 
and the Children’s Global Assessment Scores (CGAS),
48
  respectively at study entry.
29
 
Data on ICD-10 co-morbid neuropsychiatric disorders which can be subsumed under 
the DSM-5 category of autism spectrum disorder - ASD (F84.0, F84.1, F84.5, F84.9), 
hyperkinetic disorder (F90.0, F90.1, F90.2, F90.8, F90.9), major depressive disorder 
(F32-33), and intellectual disability (F70-79), were also extracted from free text and 
structured fields as previously described.
29
 TextHunter also retrieved positive mentions 
of substance misuse around first presentation, with validation metrics (PPV) for the 
following Cannabis (0.70) , Cocaine or crack (0.78), Amphetamine (0.76), and  3,4- 
Methylenedioxymethamphetamine (MDMA, 0.88); a binary ‘any use’ variable was 
created for each substance type. Using the GATE tool, we also built a rules-based NLP 
application which coded absence/presence of a 1
st
 degree relative with psychosis 
(defined as any of the study inclusion terms for psychosis but affecting parents or full 
siblings). Validation of this NLP approach was conducted against clinician review (JD 
& LP) of all patient notes from 96 randomly selected EOP cases (PPV 0.91, recall 0.73).  
 
 
Statistical Analyses 
All analyses were conducted using STATA (Version 13). The prevalence of individuals 
meeting ≥2 threshold NS, and the total number of NS items was calculated. Logistic 
regression was used to examine the demographic and baseline clinical association with   
≥2 NS profiles.  
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To examine the prospective association between baseline demographic, clinical 
exposures and MTF outcome, we excluded children who had MTF within the 60-day 
baseline period (n=20). Kaplan–Meier curves were used to illustrate survival over time 
(probability of non-development of MTF), comparing those who were and were not 
presenting with ≥2 NS at baseline. After checking proportional hazards assumptions, we 
used a Cox regression to model the association between this baseline NS profile and 
MTF over a 5-year follow-up period from first presentation, or before the age of 18 
years, whichever came first. The first model examined the crude effect of NS alone on 
MTF. Subsequent models were constructed adding potential socio-demographic, and 
clinical confounders. As sampling bias towards more severe cases could affect the 
external validity of the findings, sensitivity analyses were conducted to adjust the 
aforementioned models by adaptive function (CGAS) measures at first presentation and 
local catchment area residence status; (ii) restrict to patients who were inpatients at 
baseline line assessment.  
 
Results   
Demographic and clinical characteristics of the sample 
Demographic and clinical characteristics of the 638 patients included (124 [19.3%] of 
whom developed MTF over time) and of the NS subgroup are presented in Table 2.   
[Table 2 around here] 
Negative symptom prevalence 
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Supplementary Material 1 shows the prevalence of each NS and positive symptom, and 
summary statistics for each item using the manually-validated NLP extraction tool, in 
the total sample and the MTF subgroup. Of note, 52.4% of the MTF subgroup presented 
with ≥2 Marder Factor NS. The most prevalent NS in the MTF subgroup was emotional 
withdrawal (43.6%). The prevalence of ≥2 Marder Factor NS across diagnostic 
categories were as follows: schizophrenia- 39.2%, schizoaffective disorder- 35.3%, 
bipolar disorder- 26.1%, psychotic depression- 37.7%, drug-induced psychosis- 25.6% 
and other psychoses- 40.6%. 
Reasons for antipsychotic discontinuation  
Details on the antipsychotic treatment pathways for the 124 children who developed 
MTF are shown as Supplementary Material 2. Cases identified as having the same 
reason for antipsychotic discontinuation at first and second antipsychotic trials were 
grouped into three MTF ‘persistent reason’ groups (persistent insufficient response, 
adverse events or non-adherence). A ‘variability in reasons’ subgroup (i.e. when reasons 
were different at each antipsychotic trial) was also created. The main patterns of 
discontinuation in the MTF group were the combination of insufficient response and 
adverse events (n=32, 35.2%), and persistent adverse events (n=19, 20.9%) over time. 
Children with NS profile showed higher rates of the ‘insufficient response-and-adverse 
effect’ trajectory and lower rates of adherence-related trajectories relative to those with 
non-NS profile (Supplementary Material 2). 
Cox regression models 
Kaplan-Meier curves displaying the survival status (probability of treatment 
effectiveness or non-MTF) over time of children with or without baseline NS profiles 
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are presented as Figure 2. A logrank test showed non-NS profile at first presentation to 
services displayed significantly higher survival rate (p <.001). Unadjusted associations 
using a Cox regression model between MTF outcomes and predictor variables, 
including NS and other co-variates, are displayed in supplementary material 3. An 
adjusted Cox regression model (Table 3) showed that NS profile was associated with 
increased risk of MTF over the follow-up period (adjusted hazard ratio [aHR] 1.62, 95% 
CI 1.07–2.46; p= .02). Black ethnicity (aHR 1.78, 95% CI: 1.11–2.87; p= .02), older age 
at first presentation (aHR 1.27, 95% CI: 1.109–1.49; p= .002), comorbid diagnosis of 
ASD (aHR 1.70, 95% CI: 1.03–2.79; p= .04), and first degree relative with psychotic 
disorder (aHR 2.11, 95% CI: 1.35–3.30; p= .001) were also significantly associated with 
MTF.  
[Figure 2 and Table 3 about here] 
 
Sensitivity Analyses 
A sensitivity analysis with adjustment for all those with complete CGAS information 
and residence within the local catchment area (n=394), found NS profile was associated 
with increased risk of MTF (aHR= 1.85; 95% CI= 1.02–3.48; p=.03). The analyses 
including only those individuals who were inpatients (n=260, 40.8%) at first 
presentation (within 60 days of accepted referral) found little change in the direction 
and magnitude of the association between NS and MTF (aHR= 1.63; 95% CI = 0.82–
3.22; p= .16), although the reduced sample affected the power of the study to detect a 
significant association.  
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Discussion 
This study shows that children and adolescents with psychosis commonly present with 
NS, with more than one third of the sample displaying NS at first presentation to 
services. Our results also show that an NS profile at first stages is a prognostic marker 
for antipsychotic treatment failure in children with EOP: approximately 30% of the 
sample with NS at baseline went on to develop MTF, representing a two-fold increased 
risk from those without NS. The treatment pathway to MTF for young people with NS 
profiles appears to be driven by a combination of limited treatment response and 
emergence of intolerable adverse effects. Older age at first episode, Black ethnicity and 
a comorbid diagnosis of ASD are also significant predictors of MTF in our sample. 
 
This is, to our knowledge, the largest naturalistic study of its kind to examine the 
prevalence of NS in EOP at first presentation to child mental health services. The study 
used an innovative text mining technique, adapted from an application in adult mental 
health records,
8
 to extract negative symptom profiles. In our study, more than one third 
of the EOP population had two or more NS at baseline, rates that are consistent with 
those reported in both child and adult-onset psychosis literature (around 30-50%).
8, 49
 
 
This is also the first study to assess the association of NS and antipsychotic treatment 
failure in first-episode EOP patients. Our results, combined with findings that NS can 
manifest in the psychosis prodrome,
50
 suggests that NS profiles could represent a 
distinct phenotypic trajectory in young people with psychotic disorders. NS are possibly 
a marker for a distinct deviant neurodevelopmental trajectory which may be harder to 
treat with conventional antipsychotics and therefore result in a more impaired illness 
course. Although no other cohorts have been used to examine MTF as an outcome in 
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EOP, our findings are consistent with evidence that NS are associated with poor clinical 
outcomes in adult and child samples, many of those using validated gold-standard 
instruments to measure negative symptoms (e.g. the PANSS).
1, 51
 Our work using text 
mining approaches for NS identification in large scale naturalistic samples of EOP 
using EHRs serves to complement the more traditional approaches using selective 
cohorts and intensive structured assessments, to inform prognostic indicators in clinical 
practice.  
 
Several alternative psychopathological processes may be driving our findings. Higher 
levels of primary NS may represent a clinical phenotype for greater levels of ‘non-
hyperdopaminergic’ processes behind psychosis development and/or remission.
30-31, 52
  
Hence, NS may help identify a subgroup of patients with positive symptoms who do not 
respond well to antipsychotics, and are at higher risk of developing MTF. Our findings 
suggest NS in adolescents, alongside other factors including ethnicity, family history 
and neurodevelopmental co-morbidity may delineate “hard to treat” subgroups. These 
groups may benefit from more careful monitoring and quicker access to additional 
interventions beyond antipsychotic medication.
53
 Follow-up was conducted for the 
sample for up to five years, so it is important to understand that antipsychotic 
medication may still successfully reduce positive psychotic symptoms in these groups, 
but NS and other MTF risk factors may moderate the association between positive 
symptom reduction and the protective factors required for a sustained remission. Our 
findings also highlight the need for research involving agents that work on alternative 
pathophysiological pathways (e.g. the glutamate system) which may be of greater 
relevance to these subgroups, given their potential effectiveness at treating both the NS 
and the positive symptoms of those with psychosis. 
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Our findings support the notion that NS are intrinsic to early-onset psychosis (across 
different psychosis diagnostic categories) and are already present during the first 
psychotic break. In regard to the prevalence across the different psychosis disorder 
classifications, in our sample NS were present in about one third of all EOP diagnostic 
subgroups, with slightly higher rates in those with non-affective psychosis. This 
suggests that in EOP, differences between psychosis diagnostic categories (especially 
between schizophrenia and affective psychoses) are quantitative rather than qualitative 
in nature, and all diagnoses are associated with presence of impairing symptoms (as 
reflected by similar rates of NS). Further research using transdiagnostic approaches, as 
illustrated in this study, are needed to advance in the understanding of the 
physiopathology and predictive value of NS across disorders. 
 
The main strengths of this study include the use of a large historical cohort of first-
episode EOP, which provides a ‘real world’ sample of young people accessing inpatient 
and outpatient first episode psychosis CAMH services. Selecting an early-onset sample 
at first episode, reduces the potential bias incurred through unknown treatment 
exposures. The large sample size, and relative long duration of assessment provides 
sufficient power to estimate the association between NS and MTF even after adjustment 
for a number of potential clinical confounders, including psychotic disorder 
classification, family history, positive symptoms, substance misuse, 
neurodevelopmental and depressive disorder comorbidity. Using a clinical rater review 
of the whole electronic health record for sub-sets of patients allowed us to compute 
performance estimates of the different text extraction tools used in the study and select 
the most accurate ones, and mitigation of misclassification errors. This work using text 
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mining approaches for NS identification in large scale naturalistic samples of EOP 
using EHRs serves to complement the more traditional approaches using selective 
cohorts and intensive structured assessments, to inform prognostic indicators in clinical 
practice. It is important to recognise that even the most accurate NLP applications will 
be limited by the text held within clinical records, and unlikely to identify NS as 
accurately as specialised rating scales. However, as with most structured psychiatric 
assessments, clinicians tend to shun structured templates or drop-down options when 
keeping a record of their daily practice,
54-55
 so the free-text note persists as the 
predominant method of recording clinical information.
56
 This was certainly reflected in 
our EOP samples, as we were unable to detect any young people who had undergone a 
comprehensive assessment for negative symptoms using a standardised instrument at 
first presentation.  
 
Results derived from the EOP sample should be interpreted in the context of several 
limitations, some of which have been covered in previous work.
29
 In relation to the 
findings specific to this study, it was difficult to ascertain whether extracted NS were 
primary or secondary in nature, we assume that as NS were rated early (i.e. within 60 
days of presentation to services and potentially prior or at the point of starting initial 
antipsychotic treatment), and excluding the presence of psychomotor retardation from 
the total NS counting, the NS we detect are mainly (but not only) primary in character. 
In regard to the MTF definition, we were unable to obtain relevant antipsychotic data 
such as maximum daily antipsychotic dose, antipsychotic serum levels, or structured 
assessments of tolerability, which may have provided more objective assessments of 
treatment failure.  Besides, by rating treatment failure to one of four potential categories 
at each point of discontinuation/treatment failure, we may have underestimated the 
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contribution of other underlying reasons to treatment failure. As with all observational 
studies, our findings may be limited by residual confounding, for example we were 
unable to adjust for the duration of untreated psychosis – which could be explanatory 
factors for older age being associated with MTF. Another related limitation includes the 
restriction of age to the clinical samples, so that all clinical outcomes occurred prior to 
age 18. One of the reasons we imposed this was to reduce the impact of clinician 
heterogeneity as a residual confounder. Children with long term conditions, such as 
psychosis, experience very different treatment environments when they move from 
CAMHS to adult psychiatric services,
57
 and this heterogeneity may have considerable 
influence on the way clinical data is recorded, as well as the mental health treatments 
offered and outcomes obtained.
58
 Finally, there is a chance that not all children and 
adolescents experiencing a first-episode psychosis within the catchment area (who 
access clinical services) would have presented to SLaM CAMHs, nor given potential 
changes in residence away from SLaM services,  were all young peoples’ psychiatric 
care captured by the health record system over the course of follow-up. Given the mean 
duration of follow-up was lower in the NS group, we suspect that this may have led to 
an underestimation of the NS-MTF effect we report.  Furthermore, the impact of 
potential loss to follow-up or of non-actual first presentation to services is likely to be 
limited, as we conducted a sensitivity analyses which took account of residence within 
the local catchment which showed little difference from whole sample findings.    
 
In summary, our study demonstrated that there is a high prevalence of negative 
symptoms in early-onset psychosis around patients’ first presentation to services and 
across psychosis diagnosis classifications. The finding supports the hypothesis that 
presence of these symptoms around the first stages of the illness identify a subset of 
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children and adolescents who may be at higher risk of responding poorly to 
antipsychotics, both through refractory symptoms and high sensitivity to side-effects. 
Optimisation of current pharmacological and non-pharmacological strategies for these 
patients, and further research involving agents that better target negative symptoms are 
warranted. 
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Table 1. Selection of negative symptoms from electronic health records and their 
equivalence to the Marder Negative Factor items within the PANSS 
Items extracted from 
electronic health record 
PPV/sensitivity Marder Negative Factor items within the 
PANSS 
Blunted affect 0.93/0.83 N1. Blunted affect 
Emotional withdrawal 0.85/0.74 N2. Emotional withdrawal 
Poor rapport 0.91/0.77 N3. Poor rapport 
Social isolation  
0.94/0.96 
N4. Passive apathetic social withdrawal 
G16. Active social avoidance 
Poverty of speech  
Mutism 
0.80/0.73 
0.99/0.94 
N6. Lack of spontaneity & conversation flow 
Psychomotor retardation 
(dropped 
a
) 
0.55/0.65 G7. Motor retardation 
aDropped from the study due to low PPV (0.55) and sensitivity (0.65) of the ´free text’ extraction tool, and due 
to its being recorded mainly as secondary negative symptom. 
Note: PANSS: Positive and Negative Syndrome Scale; PPV: positive predictive value 
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Table 2. Comparison between young people with early-onset psychosis at first presentation with and without 
≥ two negative symptoms documented 
Sample characteristics 
Non-NS group 
(n = 399) 
NS group 
(n = 239) 
 
OR;
 
p-value 
MTF status, N(%) 59 (14.8) 65 (27.2) 2.15 (1.45-3.20) *** 
Gender, Female, N(%) 192 (48.1) 117 (48.9) 1.03 (0.75-1.42) 
Age at referral (mean, SD) 15.4 (1.9) 15.9 (1.9) 1.17 (1.06-1.28) *** 
Age of reaching MTF (mean, SD)  16.5 (1.3) 16.0 (0.19) 0.79 (0.61-1.04) 
Duration of follow-up (days), mean (SD) 721.4 (529.9) 590.5 (458.0) 0.995 (0.991-0.998) ** 
Ethnicity, N(%)    
      White 204 (51.1) 93 (38.9) Reference 
      Black 113 (28.3) 96 (40.2) 1.86 (1.29-2.67) 
      Asian 18 (4.5) 21 (8.8) 2.56 (1.30-5.03) 
      Mixed 47(11.8) 27(11.3) 1.26 (0.74-2.15) 
      Not Stated 17 (4.3) 2 (0.8) 0.25 (0.06-1.14) 
Neighbourhood Characteristics, N(%)
 a
    
     1
st
 (Least Deprived) 104 (27.1) 61 (25.9) Reference 
     2nd 90 (23.4) 62 (26.4) 1.17 (0.75-1.42) 
     3rd 94 (24.5) 57 (24.3) 1.03 (0.66-1.63) 
    4
th
 (Most Deprived) 96 (25.0) 55 (23.4) 0.98 (0.62-1.54) 
First ICD-10 psychosis diagnosis, N(%)    
    Other Psychoses
b 
63 (15.8) 43 (17.9) Reference 
    Bipolar Disorder / F30, F31 31 (7.8) 11 (4.7) 0.57 (0.24-1.15) 
    Drug-induced psychosis / F1x.x5 29 (7.3) 10 (4.2) 0.51 (0.22-1.14) 
    Schizophrenia / F20 222 (55.6) 143 (59.8) 0.94 (0.61-1.46) 
    Schizoaffective / F25 11 (2.8) 6 (2.5) 0.80 (0.27-2.32) 
    Psychotic Depression / F32.3, F33.3 43 (10.8) 26 (10.9) 0.89 (0.47-1.65) 
Co-morbid neuropsychiatric disorders, N(%)    
   Autism Spectrum Disorder 75 (18.8) 39 (16.3) 0.84 (0.55-1.29) 
   Hyperkinetic Disorder 33 (8.27) 7 (2.9) 0.33 (0.15-0.77)** 
   Intellectual Disability 43 (10.8) 22 (9.2) 0.84 (0.49-1.44) 
   Major Depressive Disorder 108 (27.1) 66 (27.6) 1.03 (0.72-1.48) 
First degree relative with psychotic disorder 86 (21.6) 51 (21.3) 0.99 (0.67-1.46) 
Illness severity/ Functioning    
        Admission at presentation, N(%) 90 (22.6) 170 (71.1) 8.5 (5.9-12.2)*** 
        CGAS score (mean, SD)
b
 42.1 (15.3) 33.7 (15.4) 0.97 (0.95-0.98)*** 
Positive symptoms     
     1
st
 (lowest quartile of symptom items recorded) 61 (15.3) 11 (4.6) Reference 
     2
nd
 79 (19.8) 27 (11.3) 1.90 (0.87 – 4.21) 
     3
rd
 137 (34.3) 84 (35.2) 3.40 (1.69-6.83) *** 
    4
th
 (highest quartile of symptoms items recorded) 122 (30.6) 117 (49.0) 5.31 (2.67-10.6) *** 
 Substance misuse    
     Cannabis 171 (42.9) 113 (39.5) 1.20 (0.87-1.65) 
     Cocaine or crack 65 (16.3) 39 (16.3) 1.02 (0.65-1.54) 
     Amphetamines 14 (3.5) 5 (2.1) 0.59 (0.21-1.65) 
     MDMA 12 (3.0) 4 (1.7) 0.55 (0.18-1.72) 
*p < .05; **p < .01; ***p < .001; % Refers to percentages within columns, for whom information was available 
a
 Missing cases =19; 
b 
Data available in a subsample of 384, 
b 
Other Psychoses: an ICD-10 diagnosis of ‘brief 
psychotic disorder (F23)’, ‘delusional disorder (F22), ‘shared psychotic disorder’, or ‘psychosis not otherwise 
specified (NOS)’.Note: CGAS: Children’s Global Assessment Scale; MTF: multiple treatment failure; NS: negative 
symptoms. 
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Table 3. Cox regression models for the association between negative symptom profile at first 
presentation and multiple treatment failure over time in early-onset psychosis (n=618) 
Multiple treatment failure 
Socio-demographic 
adjustment 
aH.R. (95% CI) 
+ diagnosis and severity  
aH.R. (95% CI) 
+ substance misuse and 
family history 
aH.R. (95% CI) 
≥2 baseline Marder NS 1.66 (1.12 – 2.42)* 1.59 (1.06 – 2.40)* 1.62 (1.07 – 2.46)* 
Female gender 1.08 (0.73-1.62) 1.15 (0.76-1.74) 1.07 (0.71-1.64) 
Mean age at referral (s.d) 1.25 (1.09-1.45) ** 1.29 (1.10-1.49) ** 1.27 (1.09-1.49) ** 
Ethnicity, N (%)    
      White Reference Reference Reference 
      Black 1.95 (1.23-3.09)** 1.72 (1.08-2.76)* 1.78 (1.11-2.87)* 
      Asian 1.16 (0.48- 2.77) 1.10 (0.46-2.67) 1.33 (0.58-3.26) 
      Mixed 1.51 (0.80- 2.86) 1.43 (0.75-2.73) 1.63 (0.84-3.17) 
      Not Stated ------
a
 - - 
Neighbourhood Characteristics, N(%)
 a
    
     1
st
 (Least Deprived) Reference Reference Reference 
     2nd 0.60 (0.35-1.04) 0.69 (0.39-1.19) 0.66 (0.37-1.17) 
     3rd 0.55( 0.31-0.96)* 0.61 (0.35-1.08) 0.56 (0.31-0.98) 
    4
th
 (Most Deprived) 0.55 (0.31-0.97)* 0.61 (0.34-1.08) 0.62 (0.34-1.11) 
First ICD-10 psychosis diagnosis, N(%)    
    Other Psychoses
b 
  Reference Reference 
    Bipolar Disorder / F30, F31   1.57 (0.69-3.56) 1.54 (0.67-3.56) 
    Drug-induced psychosis / F1x.x5   0.82 (0.27-2.51) 0.92 (0.29-2.96) 
    Schizophrenia / F20   0.85 (0.50-1.45) 0.78 (0.45-1.32) 
    Schizoaffective / F25   2.42 (0.87-6.85) 2.22 (0.78-6.34) 
    Psychotic Depression / F32.3, F33.3   1.39 (0.62-3.08) 1.15 (0.50-2.60) 
Co-morbid neuropsychiatric disorders, N(%) 
    
   Autism Spectrum Disorder   1.73 (1.06-2.82) 1.70 (1.03-2.79) 
   Other neurodevelopmental disorder   0.74 (0.41-1.33) 0.68 (0.38-1.24) 
   Major Depressive Disorder   0.68 (0.39-1.15) 0.69 (0.41-1.20) 
     
Positive symptoms      
     1
st
 (lowest quartile)   Reference Reference 
     2
nd
   0.89 (0.36 – 2.15) 0.83 (0.32 – 2.13) 
     3
rd
   1.18 (0.53-2.65)  1.09 (0.48-2.46)  
    4th (highest quartile)   1.97 (0.92-4.21)  1.83 (0.84-3.98)  
First degree relative with psychotic disorder 
    
2.11 (1.35-3.30)** 
 Substance misuse      
     Cannabis     1.07 (0.67-1.70) 
     Cocaine or crack     0.68 (0.36-1.31) 
     Amphetamines     1.20 (0.27-5.43) 
     MDMA     0.55 (0.07-4.34) 
*
p< .05; **p < .01; 
a 
Variable dropped due to 0 values in cell. 
b 
See corresponding footnote table 2; Note: H.R.: hazard ratio; 
MTF: multiple treatment failure; NS: negative symptoms 
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Figure 1: Flowchart of study selection and analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity analyses restricted to samples: 
1) Adjusting for fully complete adaptive 
function measures and residence within the 
local catchment. 
2) Admitted patients at baseline assessment 
Cases reaching MTF threshold within 60 
days of entering the study (n=20) 
All MTF case notes hand 
searched and reasons coded. 
0.99 sensitivity, 0.74 positive 
predictive value for MTF 
638 cases 
19.7% (n=124) with 
MTF within 5 years 
Survival 
Analysis 
(n=618) 
 
MTF 
validation 
43 cases re-recoded as non 
MTF within 5 years or before 
18 years old, whichever came 
first 
1033 cases < 18 years old identified 
with at least one psychotic disorder 
reference in the electronic health 
record 
Filter applied for ‘clinically relevant’ 
psychotic disorder between 10-17 years 
Included cases 
N= 638 
(61% from structured 
diagnostic fields) 
Natural language extraction of ‘possible’ 
MTF outcome 
395 children and adolescents 
excluded as psychoses described as 
non-primary differential diagnosis, 
or with sub-threshold / incidental 
symptoms 
638 cases, 26.2% (n=167) initially 
identified with MTF 
Page 31 of 34
http://www.schizophreniabulletin.oupjournals.org
Schizophrenia Bulletin. For Peer Review Only
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
    
1 
 
Figure 2:  Kaplan-Meier curves displaying the survival status (probability of 
treatment effectiveness or non-MTF) over time of children with or without 
negative symptom profiles at first presentation to services. 
 
Note: NS: negative symptoms 
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Supplementary Material 1: Summary of negative and positive symptom items extracted from the EHR at first presentation to services 
in early-onset psychosis subjects 
 
 
Total sample (N= 638) MTF (N=124) Example text for NLP extraction 
Symptom categories  N(%) 
Total items 
detected  
Items detected 
mean (S.D, IQR) 
N(%) 
Total items 
detected  
Items detected 
mean (S.D, IQR) 
Positive annotation Negative annotation 
Negative items         
    Blunted affect 130 (20.3) 457 0.72 (1.6, 9) 29 (23.4) 147 1.18 (2.3, 10) 
His affect remains very 
blunted 
incongruent affect, 
Stable affect 
    Emotional      
    withdrawal 
214 (33.5) 848 1.33 (2.3, 12) 54 (43.6) 258 2.10 (2.9, 11) 
mother described her as 
becoming withdrawn, 
not communicating; 
not sad or withdrawn 
during the assessment 
    Poor rapport 62 (9.7) 176 0.28  (0.9, 6) 18 (14.5) 61 0.49 (1.2, 5) 
He had poor rapport, 
very limited rapport 
We established a good 
rapport 
    Social isolation  51 (8.0) 226 0.35 (1.3, 8) 14 (11.3) 88 0.71(2.3, 6) 
He withdrew socially 
from friends and family, 
no evidence of being 
socially withdrawn 
    Poverty of speech 32 (5.0) 84 0.13 (0.6, 4) 8 (6.5) 17 0.13 (0.6, 4) 
He has poverty of 
speech 
Speech normal, no 
pressure or poverty of 
speech apparent 
    Mutism 66 (10.3) 462 0.72 (3.6, 28) 25 (20.2) 203 1.67(5.6, 28) 
She has periods of 
'mutism'   
Mother denied he had 
any periods of being 
mute 
≥ 2 NS 239 (37.5) - - 65 (52.4) - -   
Positive items          
    Delusions 277 (43.4) 1145 1.8 (4.6, 2) 74 (60) 449 3.62 (8.6, 3) 
continued to express 
delusional ideas 
No evidence of 
delusions,  
    Hallucinations 483 (76.4) 5226 8.2 (12.5, 18) 103 (83.0) 1761 14.2 (18.4, 17 ) 
visual distortions and 
auditory hallucinations 
No evidence of 
responding to any 
hallucinations 
    Paranoid ideation 427 (66.9) 3579 5.61 (11.9, 6) 94 (75.8) 1237 10.0 (21.2, 10) 
He said the neigbours 
cause him to feel 
paranoid 
No appearance of 
paranoia, denied 
paranoid feelings 
    Persecutory ideation 180 (28.4) 540 0.84 (2.3, 1) 45 ( 36.3) 152 1.22 (3.3, 1) 
She suffered 
persecutory delusion 
He denied any worries 
of persecution 
Note:  EHR: Electronic Healthcare Record; IQR: interquartile range; MTF: multiple treatment failure; NLP: natural language processing; NS: negative symptoms; S.D: 
Standard Deviation  
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Supplementary Material 2: Reasons for multiple treatment failure in young people with 
early-onset psychosis, with and without negative symptoms at first presentation 
 
 
 N (%) of individuals
b
 
Reasons for MTF
a Non - NS 
(n = 41) 
NS 
(n = 50) 
Persistent insufficient response 6 (14.6) 7 (14.0) 
Persistent adverse effects 9 (21.9) 10 (20.0) 
Persistent non-adherence 2 (4.9) 3 (6.0) 
Variability in reasons    
• Insufficient response and adverse effects 11 (26.9) 21 (42.0) 
• Insufficient response and non-adherence 3  (7.3) 4 (8.0) 
 
• Adverse effects and non-adherence 10 (24.4) 5 (10.0) 
a Comparison in reasons for MTF between Non-NS and NS groups; fisher exact 
test, p=0.49 
b In all cells, % refers to percentages (within columns) of individuals for whom 
information on main reason of discontinuation was available (n=91). Excluded 
due to no reason ' or 'other reason' ascertained were: Non-NS n= 18 (31%); NS 
group n=15 (23%) 
Note: MTF: multiple treatment failure; NS: negative symptoms 
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 Supplementary Material 3: Baseline characteristics profile at first presentation and association with 
multiple treatment failure over time in early-onset psychosis (n=618) 
Baseline characteristics Non MTF Sample MTF sample Crude H.R. (95% CI) 
≥2 baseline Marder NS 167 (33.7)     49 (46.2) 1.98 (1.35 – 2.91)** 
Female gender 238 (48.0)   57 (53.8) 1.12 (0.76-1.65) 
Mean age at referral (s.d) 15.6 (1.9) 15.3 (1.7) 1.30 (1.13-1.50) *** 
Ethnicity, N(%)    
      White 243 (48.9) 43 (40.6) Reference 
      Black 150 (30.2) 44 (41.5) 1.64 (1.08-2.49)* 
      Asian 30 (6.1) 6 (5.7) 1.31 (1.30-3.03) 
      Mixed 56 (11.3) 13 (12.3) 1.45 (0.77-2.69) 
      Not Stated 17 (3.4) 0 (0) - 
Neighbourhood Characteristics, N(%)
 a    
     1st (Least Deprived) 121 (25.1) 34 (33.0) Reference 
     2nd 118 (24.4) 23 (22.1) 0.69 (0.41-1.18) 
     3rd 124 (24.7) 21 (20.6) 0.64 (0.37-1.11) 
    4th (Most Deprived) 120 (24.8) 24 (23.5) 0.66 (0.39-1.12) 
First ICD-10 psychosis diagnosis, N(%)    
    Other Psychoses
b 
81 (16.3) 21 (19.8) Reference 
    Bipolar Disorder / F30, F31 32 (6.5) 9 (8.5) 1.26 (0.57-2.76) 
    Drug-induced psychosis / F1x.x5 29 (5.9) 4 (3.8) 0.80 (0.27-2.34) 
    Schizophrenia / F20 293 (59.1) 52 (49.1) 0.79 (0.47-1.31) 
    Schizoaffective / F25 7 (1.4) 7 (6.6) 3.10 (1.31-7.33)** 
    Psychotic Depression / F32.3, F33.3 54 (10.9) 13 (12.3) 1.05 (0.52-2.10) 
Co-morbid neuropsychiatric disorders, 
N(%) 
   
   Autism Spectrum Disorder 81 (16.3) 29 (27.4) 1.24 (0.80-1.91) 
   Other neurodevelopmental disorder 80 (16.1) 16 (15.1) 0.72 (0.43-1.23) 
   Major Depressive Disorder 142  (28.6) 26 (26.4) 0.82 (0.53-1.27) 
First degree relative with psychotic 
disorder 
97 (19.6) 33 (31.3) 1.84 (1.22-2.77)** 
Illness severity/ Functioning    
        Admission at presentation, N(%) 176 (35.5) 54 (50.9) 2.33 (1.59-3.43)*** 
        CGAS score (mean, SD)
b
 39.3 (15.8) 36.2 (15.8) 0.985 (0.971-0.999)* 
Positive symptom     
     1st (lowest quartile) 57 (11.5) 9 (8.5) Reference 
     2
nd
 92 (18.5) 11 (10.4) 0.89 (0.36 – 2.15) 
     3
rd
 183 (36.9) 31 (29.3) 1.35 (0.64-2.84)  
    4
th
 (highest quartile) 164 (30.1) 55 (51.9) 2.42 (1.19-4.89)* 
 Substance misuse    
     Cannabis 219 (44.2) 44 (41.5) 1.22 (0.83-1.80) 
     Cocaine or crack 84 (16.4) 14 (13.2) 0.94 (0.53-1.64) 
     Amphetamines 16 (3.3) <5 (<5) 1.17 (0.32-3.71) 
     MDMA 14 (2.8) <5 (<5) 0.51 (0.07-3.69) 
*p < .05; **p < .01; ***p < .001; % Refers to percentages within columns, for whom information was available 
a
 Missing cases =19; 
b 
Data available in a subsample of 384, 
b 
Other Psychoses: an ICD-10 diagnosis of ‘brief psychotic 
disorder (F23)’, ‘delusional disorder (F22), ‘shared psychotic disorder’, or ‘psychosis not otherwise specified (NOS)’.Note: 
CGAS: Children’s Global Assessment Scale; MTF: multiple treatment failure; NS: negative symptoms;  
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